Helix BioPharma
Toronto
About Helix BioPharma
Helix Biopharma is an oncology company shaping a near future where today’s hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The Company innovates from strength with a diverse, clinical-stage pipeline of drug candidates with great potential and head start, honed into first-and best-in-class oncology medicines. Our pipeline’s driving force is a proprietary technology platform of bio-conjugates that score with precision against prevalent CEACAM6-expressing cancers, including non-small cell lung cancer (NSCLC), pancreatic, colon and ovarian cancers. Its flagship candidate, Tumour Defence Breaker™ L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that modifies the microenvironment of common, hard-to-treat solid tumours, taking the brakes off the immune system’s anti-tumour defences and delivering a game-changing assist to today’s front-running anti-cancer therapies. Our pre-IND candidates include (i) an oral immune checkpoint modulator that aims to bring long-term remission within reach of patients relapsing with leukemia after allogeneic stem cell transplantation, and (ii) a pioneering oral gemcitabine chemotherapy geared to enrich the spectrum of disease-limiting and life-enhancing treatment outcomes for patients with prevalent, hard-to-treat cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $22.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2025)
- Ticker: tsx:HBP
- Website: helixbiopharma.com
- Phone: 604-428-7050
Industries & Categories
Biotechnology, Health Care, Oncology
Social Profiles
Canonical: https://fsome.com/organization/helix-biopharma-180715 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.